Aviceda

Aviceda Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, pioneering the field of glyco-immune checkpoint therapeutics. The company's proprietary HALOS platform harnesses glycobiology to modulate innate immune pathways — targeting chronic, non-resolving inflammation in ocular and systemic diseases. Its lead asset, AVD-104, is in a Phase 2b/3 clinical trial for Geographic Atrophy (a leading cause of blindness). Aviceda's pipeline addresses macular degeneration, uveitis, retinal degenerative diseases, and autoimmune conditions, combining nanoparticle technology with high-throughput ligand screening to create disease-modifying medicines.